NTLA:NASDAQ
Intellia Therapeutics Inc
၁၂.၅၈ US$
၀.၀၀%
(၀.၀၀) 1D
၁၂.၄၁ US$
arrow_downward
-၁.၃၅% (-၀.၁၇)todayPre-market
Closed: အောက် ၁၂, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NTLA...
Mkt. cap
၁၇၆.၂၈ ဋေ
Avg. vol.
၄.၉၇ သန်း
Volume
၉.၁၉ ထောင်
52-wk high
၂၈.၂၅ US$
52-wk low
၇.၉၅ US$
EPS
-၃.၃၆ US$
Beta
၁.၈၀
Shares outstanding
၁၄.၀၁ ကုဋေ
No. of employees
၃၇၇
Mkt. cap
၁၇၆.၂၈ ဋေ
Avg. vol.
၄.၉၇ သန်း
Volume
၉.၁၉ ထောင်
52-wk high
၂၈.၂၅ US$
52-wk low
၇.၉၅ US$
EPS
-၃.၃၆ US$
Beta
၁.၈၀
Shares outstanding
၁၄.၀၁ ကုဋေ
No. of employees
၃၇၇
News stories
From web sources and news partners
Investing.com Canada
·
ပြီးခဲ့သည့် ၁ နာရီ
Intellia Therapeutics names Jing Marantz as chief medical officer By Investing.com
Intellia Therapeutics
·
ပြီးခဲ့သည့် ၁ နာရီ
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees၃၇၇
Founded၂၀၁၄
Headquartersကင်းဘရစ်ချ်, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteintelliatx.com